Construction and characterization of a recombinant human beta defensin 2 fusion protein targeting the epidermal growth factor receptor: In vitro study

Applied Microbiology and Biotechnology

Volumn 97, Issue 9, 2013, Pages 3913-3923

  Zhang, Minjing ^a   Qiu, Zhuangwei ^a   Li, Yinyu ^a   Yang, Yan ^a   Zhang, Qihao ^a   Xiang, Qi ^a   Su, Zhijian ^a   Huang, Yadong ^a  

^a JINAN UNIVERSITY   (China)

Author keywords

Cancer cell targeting; Cytotoxicity; Fusion protein; hBD2; HER2 neu; Single chain variable fragment

Indexed keywords

AFFINITY CHROMATOGRAPHY; ANTIBODIES; CELL CULTURE; CELL DEATH; CELL MEMBRANES; CHAINS; CHROMATOGRAPHY; CYTOLOGY; CYTOTOXICITY; DISEASES; ESCHERICHIA COLI; NICKEL; PROTEINS; RECOMBINANT PROTEINS; SCANNING ELECTRON MICROSCOPY; TRANSMISSION ELECTRON MICROSCOPY;

CANCER CELL TARGETING; FUSION PROTEINS; HBD2; HER2/NEU; SINGLE CHAIN VARIABLE FRAGMENTS;

CELLS;

ANTINEOPLASTIC AGENT; BETA DEFENSIN 2; CHAPERONE; EPIDERMAL GROWTH FACTOR RECEPTOR; HUMAN BETA DEFENSIN 2 NEU SINGLE CHAIN VARIABLE FRAGMENT FUSION PROTEIN; HYBRID PROTEIN; NITRILOTRIACETATE NICKEL; RECOMBINANT PROTEIN; SUMO PROTEIN; UNCLASSIFIED DRUG; BETA DEFENSIN; DEFB4A PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

ANTIBODY; BIOTRANSFORMATION; FLOW CYTOMETRY; MEMBRANE; PROTEIN; RECOMBINATION;

AFFINITY CHROMATOGRAPHY; AMINO TERMINAL SEQUENCE; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CELL AGGREGATION; CELL DEATH; CELL DISRUPTION; CELL STRUCTURE; CONTROLLED STUDY; DRUG COST; DRUG CYTOTOXICITY; DRUG EFFECT; ESCHERICHIA COLI; FLOW CYTOMETRY; GENE AMPLIFICATION; HUMAN; IMMUNOFLUORESCENCE; IN VITRO STUDY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN TARGETING; SCANNING ELECTRON MICROSCOPY; TRANSMISSION ELECTRON MICROSCOPY; UPREGULATION; WESTERN BLOTTING; GENETICS; IMMUNOLOGY; METABOLISM; TUMOR CELL LINE;

ESCHERICHIA COLI;

APOPTOSIS; BETA-DEFENSINS; CELL LINE, TUMOR; CHROMATOGRAPHY, AFFINITY; ESCHERICHIA COLI; HUMANS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECOMBINANT FUSION PROTEINS; SINGLE-CHAIN ANTIBODIES;

EID: 84885945933     PISSN: 01757598     EISSN: 14320614     Source Type: Journal    
DOI: 10.1007/s00253-012-4257-z     Document Type: Article

References (32)

1. Asano R, Sone Y, Makabe K, Tsumoto K, Hayashi H, Katayose Y, Unno M, Kudo T, Kumagai I (2006) Humanization of the bispecific epidermal growth factor receptor CD3 diabody and its efficacy as a potential clinical reagent. Clin Cancer Res 12:4036-4042
2. Biragyn A, SurenhuM, Yang D, Ruffini PA, Haines BA, Klyushnenkova E, Oppenheim JJ, Kwak LW (2001) Mediators of innate immunity that target immature, but notmature, dendritic cells induce antitumor immunity when genetically fused with nonimmunogenic tumor antigens. J Immunol 167:6644-6653
3. Bowdish DM, Davidson DJ, Hancock RE (2006) Immunomodulatory properties of defensins and cathelicidins. Curr Top Microbio Immunol 306:27-66
4. Bruell D, Stöcker M, Huhn M, Redding N, Küpper M, Schumacher P, Paetz A, Bruns CJ, Haisma HJ, Fischer R, Finnern R, Barth S (2003) The recombinant anti-EGF receptor immunotoxin 425 (scFv)-ETA′ suppresses growth of a highly metastatic pancreatic carcinoma cell line. Int J Oncol 23:1179-1186
5. Butt TR, Edavettal SC, Hall JP, Mattern MR (2005) SUMO fusion technology for difficult-to-express proteins. Protein Expr Purif 43:1-9
6. Chen X, Niyonsaba F, Ushio H, Hara M, Yokoi H, Matsumoto K, Saito H, Nagaoka I, Ikeda S, Okumura K, Ogawa H (2007) Antimicrobial peptides human beta-defensin (hBD)-3 and hBD-4 activate mast cells and increase skin vascular permeability. Eur J Immunol 37:434-444
7. Corrales-Garcia LL, Possani LD, Corzo G (2011) Expression systems of human β-defensins: vectors, purification and biological activities. Amino Acids 40:5-13
8. Coussens L, Yang-Feng TL, Liao YC, Chen E, Gray A, McGrath J, Seeburg PH, Libermann TA, Schlessinger J, Francke U (1985) Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230:1132-1139
9. Fadnes B, Rekdal O, Uhlin-Hansen L (2009) The anticancer activity of lytic peptides is inhibited by heparin sulfate on the surface of the tumor cells. BMC Cancer 9:183
10. Ganz T (2003) Defensins: antimicrobial peptides of innate immunity. Nature Rev Immunol 3:710-720
11. Harder J, Bartels J, Christophers E, Schroder JM (1997) A peptide antibiotic from human skin. Nature 387:861
12. Huang Y, Su Z, Li Y, Zhang Q, Cui L, Su Y, Ding C, Zhang M, Feng C, Tan Y, Feng W, Li X, Cai L (2009) Expression and purification of GST-SUMO-MT fusion protein, and its neuronal and hepatic protection against D-galactose-induced oxidative damage in mouse model. J Pharmacol Exp Ther 329:469-478
13. Jung S, Mysliwy J, Spudy B, Lorenzen I, Reiss K, Gelhaus C, Podschun R, Leippe M, Grotzinger J (2011) Human beta-defensin 2 and beta-defensin 3 chimeric peptides reveal the structural basis of the pathogen specificity of their parent molecules. Antimicrob Agents Chemother 55:954-960
14. Kohlgraf KG, Ackermann A, Lu X, Burnell K, Bélanger M, Cavanaugh JE, Xie H, Progulske-Fox A, Brogden KA (2010) Defensins attenuate cytokine responses yet enhance antibody responses to Porphyromonas gingivalis adhesins in mice. Future Microbiol 5:115-125
15. Kubo M, Morisaki T, Kuroki H, Tasaki A, Yamanaka N, Matsumoto K, Nakamura K, Onishi H, Baba E, Katano M (2003) Combination of adoptive immunotherapy with Herceptin for patients with HER2-expressing breast cancer. Anticancer Res 23:4443-4449
16. Lichtenstein A, Ganz T, Selsted ME, Lehrer RI (1986) In vitro tumor cell cytolysis mediated by peptide defensins of human and rabbit granulocytes. Blood 68:1407-1410
17. Liu L, Roberts AA, Ganz T (2003) By IL-1 signaling, monocyte-derived cells dramatically enhance the epidermal antimicrobial response to lipopolysaccharide. J Immunol 170:575-580
18. Ma XT, Xu B, An LL, Dong CY, Lin YM, Shi Y, Wu KF (2006) Vaccine with beta-defensin 2 transduced leukemic cells activates innate and adaptive immunity to elicit potent antileukemia responses. Can Res 66:1169-1176
19. Ma C, Li Y, Li Z, Huang H, Xu K, Xu H, Bai J, Li X, Zhao G (2012) Synthesis and purification of a toxin-linked conjugate targeting epidermal growth factor receptor in Escherichia coli. Protein Expr Purif 83:1-7
20. Markeeva N, Lysovskiy I, Zhuravel E, Soldatkina M, Lyzogubov V, Usenko V, Potapov V, Pogrebnoy P (2005) Involvement of human beta-defensin-2 in proliferation of transformed cells of human cervix. Exp Oncol 27:308-313
21. Moulder SL, Arteaga CL (2003) A phase I/II trial of trastuzumab and gefitinib in patients with metastatic breast cancer that overexpresses HER2/neu (ErbB-2). Clin Breast Cancer 4:142-145
22. Niyonsaba F, Ogawa H, Nagaoka I (2004) Human beta defensin-2 functions as a chemotactic agent for tumour necrosis factor-alpha-treated human neutrophils. Immunology 111:273-281
23. Oren A, Ganz T, Liu L, Meerloo T (2003) In human epidermis, beta-defensin 2 is packaged in lamellar bodies. Exp Mol Pathol 74:180-182
24. Pazgiera M, Hooverb DM, Yang D, Lu W, Lubkowski J (2006) Human β-defensins. Cell Mol Life Sci 63:1294-1313
25. Press MF, Pike MC, Hung G, Zhou JY, Ma Y, George J, Dietz-Band J, James W, Slamon DJ, Batsakis JG (1994) Amplification and overexpression of HER-2/neu in carcinomas of the salivary gland: correlation with poor prognosis. Cancer Res 54:5675-5682
26. Selsted ME, Ouellette AJ (2005) Mammalian defensins in the antimicrobial immune response. Nat Immunol 6:551-557
27. Semple F, Webb S, Li HN, Patel HB, Perretti M, Jackson IJ, Gray M, Davidson DJ, Dorin JR (2010) Human beta-defensin 3 has immunosuppressive activity in vitro and in vivo. Eur J Immunol 40:1073-1078
28. Tsutsumi SH, Suzuki K, Akahori Y (2011) Antibody-dependent cell-mediated cytotoxicity is induced by a single-chain Fv-protein III fusion in the presence of a rabbit anti-protein III polyclonal antibody. Immunol Letters 136:44-48
29. Verri E, Guglielmini P, Puntoni M, Perdelli L, Papadia A, Lorenzi P, Rubagotti A, Ragni N, Boccardo F (2005) HER2/neu oncoprotein overexpression in epithelial ovarian cancer: evaluation of its prevalence and prognostic significance. Clinical study Oncology 68:154-161
30. Wang YS, Wang GQ, Wen YJ, Wang L, Chen XC, Chen P, Kan B, Li J, Huang C, Lu Y, Zhou Q, Xu N, Li D, Fan LY, Yi T, Wu HB, Wei YQ (2007) Immunity against tumor angiogenesis induced by a fusion vaccine with murine beta defensin 2 and mFlk-1. Clin Cancer Res 13:6779-6787
31. Winter J, Wenghoefer M (2012) Human defensins: potential tools for clinical applications. Polymers 4:691-709
32. Yang D, Chertov O, Bykovskaia SN, Chen Q, Buffo MJ, Shogan J, Anderson M, Schroder JM, Wang JM, Howard OM, Oppenheim JJ (1999) Beta-defensins: linking innate and adaptive immunity through dendritic and T cell CCR6. Science 286:525-528